Login to Your Account



Adjuvant Bell 'Tolls' for DVAX: Heplisav Panel Thumbs Down

By Randy Osborne
Staff Writer

Friday, November 16, 2012
The Toll-like receptor (TLR) 9 agonist used as an adjuvant in Dynavax Technologies Corp.'s Heplisav doomed the hepatitis B vaccine at an FDA advisory panel meeting, where members said knowledge of the drug's effects is neither broad nor diverse enough.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription